Complix to Present at Upcoming BioEquity Europe 2013: http://t.co/jzPUX0k7Bp
Reports, presentations and many other documents are downloadable and give detailed information about the life sciences sector and FlandersBio. FlandersBio members can contact us for more customised information prepared by our in-house experts.
Rapporten, presentaties en vele andere documenten verschaffen gedetailleerde informatie over de sector van de biowetenschappen en FlandersBio. Meer weten? FlandersBio-leden kunnen een beroep doen op een persoonlijke ondersteuning van onze projectmanagers.
On February 19th 2013, 24 member states of the EU signed an agreement creating a specialised patent court, the Unified Patent Court, with exclusive jurisdiction for litigation relating to European patents and European patents with unitary effect (unitary patents). Read more in this document.
This biotech guide lists the many advantages Flanders offers to prospective biotech investors, gives an overview of existing biotech activities in Flanders and Brussels, and describes the facilities available to companies considering relocating to the region.
This guide gives a clear overview of the services offered by the service & supply companies that are member of FlandersBio.
This report gives an overview of our main services and the realisations of 2011.
In this study, published by the Foreign Trade Agency in 2011, you can find an overview of the Belgian Biotech sector.
FlandersBio published an activity report for the first time this year. This report gives an overview of our four main services and the realisations of 2010.
Flanders offers many assets to startup your life sciences business. Read more about it in this document.
Deze brochure geeft een duidelijk overzicht van de financieringsbronnen waarop bedrijven een beroep kunnen doen voor het opstarten of verder uitbouwen van hun onderneming. Dit document is enkel consulteerbaar door medewerkers van FlandersBio-ledenorganisaties.
This brochure gives a clear overview of the financing sources on which companies can rely for the start-up or development of their company. This document is only consultable by FlandersBio member organisations.
This brochure, made by Flanders Investment & Trade (FIT) in collaboration with FlandersBio, provides an overview of how Flanders offers life sciences companies a long and successful tradition in discovery and development, and production and logistics.
Flanders vaccine aims to stimulate innovation in vaccine releated research & business as well as to catalyse public-private partnerships. Read more about this initiative in this brochure.
ARBOR wishes to accelerate the sustainable development and use of biomass in North West Europe, to facilitate the achievement of the EU 2020 energy objectives and to realise a world-class utilisation of biomass. Read more in this flyer.
FlandersBio is one of the partners in the European project Euregional PACT II, the Euregional Platform for Advancing Cancer Treatment. You can find more information in this flyer.
FlandersBio is one of the partners in the European project Euregional PACT II, the Euregional Platform for Advancing Cancer Treatment. Are you a research group or company looking for a cutting-edge technology or expertise related to cancer research? Discover this Euregional Pact II Toolbox.
ARBOR - an Interreg IVB NWE project - is an international effort that aims to benchmark and compare biomass use for bioenergy purposes. ARBOR brings together 13 partners from 6 European regions. This first ARBOR benchmark report drafts and compares the current situation on biomass use for bioenergy purposes in 6 countries.
FlandersBio was one of the partners in making this biotech special that appeared together with the Belgian quality newspaper De Standaard in May 2012. This special is only available in Dutch.
FlandersBio was one of the partners in making this special that appeared together with the Belgian quality newspaper De Standaard in September 2011. This special is only available in Dutch.
FlandersBio was one of the partners in making this biotech special that appeared together with the Belgian quality newspaper De Standaard in May 2011. This special is only available in Dutch.
This special focuses on medical innovation and appeared together with the Belgian quality newspaper De Standaard in February 2011. This special is only available in Dutch.
In this report, from the Dutch COGEM, you can find a detailed analysis of the fast developments in biotechnology. This report is only available in Dutch.
On 1 December 2009, the new Belgian legislation on the procurement and use of human cells and tissues entered into force. As a consequence, Belgium has satisfied the requirement to transpose into Belgian law Directive 2004/23/EC of the European Parliament and European Council of 31 March 2004.
This will ensure that Belgian legislation takes into better account the recent scientific developments in molecular and cellular biotechnology that permit innovations in treatment such as gene therapy, somatic cell therapy and tissue engineering.
A small and specialised sector of research-intensive SMEs in the biotechnology industry focuses on the discovery and development of innovative biopharmaceutical medicines for human healthcare. Within the last 10-15 years, this biopharmaceutical sector has become one of the most research-intensive sectors with a great potential for delivering innovative human medicines in the future.
This Special Report provides a comprehensive overview of signifcant trends in the life Sciences presented at the congress and offers impressions of the atmosphere in the sessions, in the exhibition and at the official reception.